APPH — Apontis Pharma AG Cashflow Statement
0.000.00%
- €93.30m
- €77.84m
- €48.47m
- 53
- 16
- 95
- 56
Annual cashflow statement for Apontis Pharma AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | GAS | GAS | GAS | GAS | GAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.18 | -0.745 | 2.69 | -11.3 | 0.754 |
Depreciation | |||||
Non-Cash Items | -0.597 | 6.26 | 2.06 | 0.182 | -6.38 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.58 | -3.83 | 4.47 | -3.36 | 0.489 |
Change in Other Assets | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 1.45 | 3.43 | 11 | -12.6 | -2.9 |
Capital Expenditures | -0.73 | -1.66 | -3.28 | -3.26 | -2.34 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.048 | -0.114 | 0.599 | 0.329 | 0.015 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.777 | -1.77 | -2.68 | -2.93 | -2.33 |
Financing Cash Flow Items | -0.002 | -7.52 | 0 | -0 | -0.135 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.002 | 20.1 | -1.84 | 6 | -6.13 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.672 | 21.8 | 6.5 | -9.53 | -11.4 |